Trial Profile

Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Levosimendan (Primary)
Indications Amyotrophic lateral sclerosis
Focus Registrational; Therapeutic Use
Acronyms REFALS
Sponsors Orion; Orion Pharma

Most Recent Events

22 Apr 2021 Results assessing how clinical chemistry measurements from the REFALS trial correlate with amyotrophic lateral sclerosis disease course to elucidate their potential as biomarkers of disease, presented at the 73rd Annual Meeting of the American Academy of Neurology.
22 Apr 2021 Results assessing the association of baseline characteristics with response to levosimendan in people with amyotrophic lateral sclerosis (ALS), were presented at the 73rd Annual Meeting of the American Academy of Neurology.
09 Oct 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com